Compounds target cancer stem cells

New compounds that target leukemia stem cells are moving into the clinic this summer. But researchers have yet to pin down exactly how some of these compounds do their job. Today at the International Society for Stem Cell Research's (ISSCR) annual meeting, linkurl:Craig Jordan;http://www.urmc.rochester.edu/GEBS/faculty/Craig_Jordan.htm from the University of Rochester presented his group's recent work on a compound TDZD-8, which was originally developed to inhibit GSK-3, and potentially treat A

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
New compounds that target leukemia stem cells are moving into the clinic this summer. But researchers have yet to pin down exactly how some of these compounds do their job. Today at the International Society for Stem Cell Research's (ISSCR) annual meeting, linkurl:Craig Jordan;http://www.urmc.rochester.edu/GEBS/faculty/Craig_Jordan.htm from the University of Rochester presented his group's recent work on a compound TDZD-8, which was originally developed to inhibit GSK-3, and potentially treat Alzheimer's disease. Jordan's group linkurl:reported;http://www.ncbi.nlm.nih.gov/pubmed/17785584?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum last year that TDZD-8 is cytotoxic exclusively for malignant leukemia stem cells; the compound caused the death of leukemia and related disease stem cells within just 15 minutes of being applied to the cell samples. Further investigation showed that the cancer stem cells' membranes break down just before cell death. Jordan's team has not come closer to understanding how the compound is able to achieve this dramatic effect. When an audience member asked just this question during Jordan's presentation this morning, Jordan answered that the membrane degradation leads his team to believe that the toxicity may stem from induced autophagy, rather than apoptosis. Regardless of some of the missing links in the compound's mechanism of action, Jordan said that clinical trials on TDZD-8 for leukemia are scheduled to begin this summer. Along with other linkurl:novel approaches,;http://www.the-scientist.com/2008/4/1/89/1/ targeting leukemia's earliest progenitors may be stem cell science's answer to this intractable disease.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Andrea Gawrylewski

    This person does not yet have a bio.
Share
Image of a woman in a microbiology lab whose hair is caught on fire from a Bunsen burner.
April 1, 2025, Issue 1

Bunsen Burners and Bad Hair Days

Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.

View this Issue
Conceptual image of biochemical laboratory sample preparation showing glassware and chemical formulas in the foreground and a scientist holding a pipette in the background.

Taking the Guesswork Out of Quality Control Standards

sartorius logo
An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

sartorius logo
Unlocking the Unattainable in Gene Construction

Unlocking the Unattainable in Gene Construction

dna-script-primarylogo-digital
Concept illustration of acoustic waves and ripples.

Comparing Analytical Solutions for High-Throughput Drug Discovery

sciex

Products

Green Cooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Thermo Fisher Logo
Singleron Avatar

Singleron Biotechnologies and Hamilton Bonaduz AG Announce the Launch of Tensor to Advance Single Cell Sequencing Automation

Zymo Research Logo

Zymo Research Launches Research Grant to Empower Mapping the RNome

Magid Haddouchi, PhD, CCO

Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer